Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors
Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: Karger
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: Karger
Subjects
More information
Scope and Contents
Contents
Purpose: To determine the maximum-tolerated doses (MTDs) and the dose-limiting toxicities (DLTs) of the weekly administration of docetaxel and pegylated liposomal doxorubicin (PEG-LD) in patients with advanced solid tumors. Patients and Methods: Forty-eight patients with solid tumors were enrolled in the study. Dose escalations of both drugs were g...
Alternative Titles
Full title
Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1159_000087908
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1159_000087908
Other Identifiers
ISSN
0030-2414
E-ISSN
1423-0232
DOI
10.1159/000087908
